Shandong Buchang Pharmaceuticals Co., Ltd. (SHA: 603858)
China
· Delayed Price · Currency is CNY 14.61
-0.20 (-1.35%)
Sep 6, 2024, 3:00 PM CST
Shandong Buchang Pharmaceuticals Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Operating Revenue | 11,703 | 13,229 | 14,942 | 15,755 | 15,983 | 14,245 | Upgrade
|
| Other Revenue | 16.51 | 16.62 | 9.62 | 7.36 | 23.24 | 10.86 | Upgrade
|
| Revenue | 11,719 | 13,245 | 14,951 | 15,763 | 16,007 | 14,255 | Upgrade
|
| Revenue Growth (YoY) | -20.87% | -11.41% | -5.15% | -1.52% | 12.28% | 4.32% | Upgrade
|
| Cost of Revenue | 4,489 | 4,321 | 4,268 | 4,134 | 3,739 | 2,388 | Upgrade
|
| Gross Profit | 7,230 | 8,924 | 10,683 | 11,629 | 12,268 | 11,867 | Upgrade
|
| Selling, General & Admin | 5,986 | 7,365 | 8,387 | 9,237 | 9,212 | 8,886 | Upgrade
|
| Research & Development | 356.81 | 335.08 | 284.12 | 408.6 | 533.42 | 505.36 | Upgrade
|
| Other Operating Expenses | 307.9 | 181.03 | 232.07 | 226.9 | 234.55 | 222.42 | Upgrade
|
| Operating Expenses | 6,638 | 7,889 | 8,907 | 9,888 | 9,981 | 9,591 | Upgrade
|
| Operating Income | 591.61 | 1,035 | 1,776 | 1,741 | 2,287 | 2,276 | Upgrade
|
| Interest Expense | -119.94 | -109.93 | -135.1 | -167.29 | -145.05 | -136.78 | Upgrade
|
| Interest & Investment Income | 10.1 | 40.12 | 22.61 | 41.34 | 32.9 | 77.88 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.18 | 0.08 | 0.45 | -0.12 | 0.04 | 0.07 | Upgrade
|
| Other Non Operating Income (Expenses) | 4.31 | -9.87 | -11.43 | -6.73 | 9.5 | 6.27 | Upgrade
|
| EBT Excluding Unusual Items | 486.24 | 955.88 | 1,652 | 1,608 | 2,184 | 2,223 | Upgrade
|
| Impairment of Goodwill | -598.03 | -598.03 | -2,943 | -10.15 | -0.24 | - | Upgrade
|
| Gain (Loss) on Sale of Investments | -6.49 | -2.36 | -56.79 | -60 | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | -2.52 | -2.47 | -0.66 | -0.59 | -0.54 | -3.45 | Upgrade
|
| Asset Writedown | -0.9 | -0.3 | - | - | - | 0.02 | Upgrade
|
| Other Unusual Items | 55.94 | 41.84 | 88.51 | 176.49 | 177.25 | 194.88 | Upgrade
|
| Pretax Income | -65.76 | 394.56 | -1,259 | 1,714 | 2,361 | 2,415 | Upgrade
|
| Income Tax Expense | 284.82 | 242.69 | 331.59 | 478.29 | 517.55 | 451.48 | Upgrade
|
| Earnings From Continuing Operations | -350.58 | 151.87 | -1,591 | 1,235 | 1,843 | 1,963 | Upgrade
|
| Minority Interest in Earnings | 154.83 | 167.11 | 61.24 | 53.84 | 17.75 | -17.23 | Upgrade
|
| Net Income | -195.75 | 318.97 | -1,530 | 1,289 | 1,861 | 1,946 | Upgrade
|
| Net Income to Common | -195.75 | 318.97 | -1,530 | 1,289 | 1,861 | 1,946 | Upgrade
|
| Net Income Growth | - | - | - | -30.72% | -4.37% | 3.05% | Upgrade
|
| Shares Outstanding (Basic) | 1,101 | 1,106 | 1,106 | 1,106 | 1,106 | 1,116 | Upgrade
|
| Shares Outstanding (Diluted) | 1,101 | 1,106 | 1,106 | 1,106 | 1,106 | 1,116 | Upgrade
|
| Shares Change (YoY) | -0.42% | -0.00% | -0.01% | 0.00% | -0.87% | -2.26% | Upgrade
|
| EPS (Basic) | -0.18 | 0.29 | -1.38 | 1.17 | 1.68 | 1.74 | Upgrade
|
| EPS (Diluted) | -0.18 | 0.29 | -1.38 | 1.17 | 1.68 | 1.74 | Upgrade
|
| EPS Growth | - | - | - | -30.72% | -3.54% | 5.43% | Upgrade
|
| Free Cash Flow | -381.06 | -725.52 | 2,212 | 886.98 | 1,422 | 1,959 | Upgrade
|
| Free Cash Flow Per Share | -0.35 | -0.66 | 2.00 | 0.80 | 1.29 | 1.76 | Upgrade
|
| Dividend Per Share | 0.126 | 0.126 | 0.960 | 0.360 | 0.526 | 1.614 | Upgrade
|
| Dividend Growth | -86.88% | -86.88% | 166.67% | -31.56% | -67.41% | 69.01% | Upgrade
|
| Gross Margin | 61.69% | 67.38% | 71.45% | 73.77% | 76.64% | 83.25% | Upgrade
|
| Operating Margin | 5.05% | 7.82% | 11.88% | 11.04% | 14.29% | 15.96% | Upgrade
|
| Profit Margin | -1.67% | 2.41% | -10.23% | 8.18% | 11.63% | 13.65% | Upgrade
|
| Free Cash Flow Margin | -3.25% | -5.48% | 14.80% | 5.63% | 8.89% | 13.74% | Upgrade
|
| EBITDA | 934.34 | 1,446 | 2,256 | 2,233 | 2,711 | 2,662 | Upgrade
|
| EBITDA Margin | 7.97% | 10.92% | 15.09% | 14.17% | 16.94% | 18.67% | Upgrade
|
| D&A For EBITDA | 342.74 | 410.47 | 479.96 | 492.39 | 424.55 | 386.08 | Upgrade
|
| EBIT | 591.61 | 1,035 | 1,776 | 1,741 | 2,287 | 2,276 | Upgrade
|
| EBIT Margin | 5.05% | 7.82% | 11.88% | 11.04% | 14.29% | 15.96% | Upgrade
|
| Effective Tax Rate | - | 61.51% | - | 27.91% | 21.92% | 18.70% | Upgrade
|
| Revenue as Reported | 11,719 | 13,245 | 14,951 | 15,763 | 16,007 | 14,255 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.